Exagen Inc.

NasdaqGM:XGN 주식 보고서

시가총액: US$72.3m

Exagen 관리

관리 기준 확인 2/4

Exagen CEO는 John Aballi, Oct2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 931.95K, 56.3% 로 구성됩니다. 56.3% 급여 및 43.7% 보너스(회사 주식 및 옵션 포함). 는 $ 1.41M 가치에 해당하는 회사 주식의 1.95% 직접 소유합니다. 1.41M. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 4.9 년입니다.

주요 정보

John Aballi

최고 경영자

US$932.0k

총 보상

CEO 급여 비율56.3%
CEO 임기2.1yrs
CEO 소유권2.0%
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간4.9yrs

최근 관리 업데이트

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Exagen appoints John Aballi as CEO

Oct 17

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Aug 06
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07
Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03
Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05
Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

CEO 보상 분석

John Aballi 의 보수는 Exagen 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$17m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$932kUS$525k

-US$24m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$35m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$1mUS$111k

-US$47m

보상 대 시장: John 의 총 보상 ($USD 931.95K )은 US 시장( $USD 649.63K ).

보상과 수익: John 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

John Aballi (39 yo)

2.1yrs

테뉴어

US$931,950

보상

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...


리더십 팀

이름위치테뉴어보상소유권
Tina Nova
Executive Chairman of the Board of Directors5.3yrsUS$132.81k0%
$ 0
John Aballi
CEO, President & Director2.1yrsUS$931.95k1.95%
$ 1.4m
Kamal Adawi
Corporate Secretary7.2yrsUS$915.09k0.30%
$ 218.9k
Jeffrey Black
Chief Financial Officerless than a year데이터 없음1.58%
$ 1.1m
Ryan Douglas
Investors Relations Officerno data데이터 없음데이터 없음
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board2.1yrs데이터 없음데이터 없음
Michael Nerenberg
Chief Medical Officer1.5yrs데이터 없음데이터 없음

2.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: XGN 의 관리팀은 경험 (평균 재직 기간 2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Tina Nova
Executive Chairman of the Board of Directors5.3yrsUS$132.81k0%
$ 0
John Aballi
CEO, President & Director2.1yrsUS$931.95k1.95%
$ 1.4m
Andrew Concoff
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board4.9yrs데이터 없음데이터 없음
Kenneth Bloom
Member of Breast Cancer Advisory Boardno data데이터 없음데이터 없음
Mark Pegram
Member of Breast Cancer Advisory Boardno data데이터 없음데이터 없음
Bruce Robertson
Independent Director5.3yrsUS$33.75k데이터 없음
Thomas Williams
Member of Breast Cancer Advisory Boardno data데이터 없음데이터 없음
Michael Press
Member of Breast Cancer Advisory Boardno data데이터 없음데이터 없음
Lyndsay Harris
Member of Breast Cancer Advisory Boardno data데이터 없음데이터 없음
Raymond Tubbs
Member of Breast Cancer Advisory Boardno data데이터 없음데이터 없음
Arthur Weinstein
Chairman of Scientific Advisory Board4.9yrsUS$130.00k데이터 없음
Frank Stokes
Independent Director3.4yrsUS$82.70k0%
$ 0

4.9yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: XGN 의 이사회경험(평균 재직 기간 4.9 년)으로 간주됩니다.